KORU Medical Q1 revenue $11.8M (+22% YoY); net loss improves to $0.8M; FY guidance reiterated

KORU Medical Systems, Inc.

2026-Q1 EPS reported -$0.02 revenue$11,764,624

Net revenue $11.8M, up 22% YoY; domestic core +11.7%, international core +35.2%, pharma services +166%.
Gross profit $7.2M (+20% YoY); gross margin 61.5% vs 62.8% on tariff costs and production timing.
Net loss improved 31% to $0.8M ($0.02 diluted EPS) from $1.2M ($0.03) in prior year.
Cash $8.8M; cash usage $0.1M in Q1. Reiterates FY2026 revenue $47.5-50.0M, positive adjusted EBITDA & cash flow.
Submitted 510(k) for Freedom Infusion System with deferoxamine; two pharma collaborations advanced to Phase III.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

KORU Medical Systems, Inc. reported first quarter ended March 31, 2026 results: revenue $11.8 million, net income $0.8 million, EPS ($0.02) per diluted share. Guidance reaffirmed.

Period: first quarter ended March 31, 2026
Revenue: $11.8 million
Net income: $0.8 million
EPS: ($0.02) per diluted share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

financial results for the first quarter ended March 31, 2026. The Company also reiterated guidance for the full year 2026. Recent Highlights ● First quarter 2026 net revenues of $11.8 million grew 22% over the prior year period ● First quarter 2026 gross profit grew 20% over the prior year period to $7.2 million, with gross margin of 61.5% ● First quarter 2026 net

View on SEC.gov

Browse all earnings releases →

KORU Medical Systems, Inc. filing history →

Source: SEC EDGAR

accession 0001161697-26-000107

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.